CXCL12 chemokine genotypes as predictive biomarkers of ovarian cancer outcome
Open Access
- 1 January 2008
- journal article
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 2 (1) , 103-106
Abstract
Ovarian cancer is an aggressive disease with high mortality. The CXCL12 chemokine has been associated with the development of this neoplasia. The aim of this study was to evaluate the genetic influence of the CXCL12-3'A polymorphism as a prognostic/predictive factor in ovarian cancer patients treated with platinum/paclitaxel chemotherapy. The mean survival rates for early stages (I/II) of the disease were statistically different according to patient genotype (96 months for GG and 57 months for A carrier genotypes; p=0.017). The mean progression-free interval was statistically lower in patients with early stages (I/II) of the tumour carrying the A allele (55 months) than in those carrying the GG genotype (91 months; P=0.009). The CXCL12-3'A polymorphism leads to a poorer response to chemotherapy with cisplatin/paclitaxel, and diminishes the mean survival rate and the progression-free interval in patients with ovarian cancer. CXCL12-3'A may therefore serve as an important predictive biomarker for the determination of outcome in ovarian cancer.Keywords
This publication has 23 references indexed in Scilit:
- CXCL12-3′A Polymorphism and lung cancer metastases protection: new perspectives in immunotherapy?Cancer Immunology, Immunotherapy, 2005
- Stromal cell-derived factor-1α (SDF-1α/CXCL12) stimulates ovarian cancer cell growth through the EGF receptor transactivationExperimental Cell Research, 2005
- Stromal cell-derived factor-1 (SDF-1) alleles and susceptibility to breast carcinomaCancer Letters, 2005
- A multicenter phase II study of gemcitabine, paclitaxel, and cisplatin in chemonaïve advanced ovarian cancerGynecologic Oncology, 2005
- CXCR4-mediated adhesion and MMP-9 secretion in head and neck squamous cell carcinomaCancer Letters, 2004
- Cytotoxicity of the novel anti-cancer drug rViscumin depends on HER-2 levels in SKOV-3 cellsBiochemical and Biophysical Research Communications, 2004
- The significance of cancer cell expression of the chemokine receptor CXCR4Seminars in Cancer Biology, 2004
- Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S -transferase genetic polymorphisms as predictive biomarkers of disease outcomeInternational Journal of Clinical Oncology, 2003
- Transcriptional profiling develops molecular signatures for ovarian tumorsCytometry, 2001
- Enhanced Drug Resistance in Cells Coexpressing ErbB2 with EGF Receptor or ErbB3Biochemical and Biophysical Research Communications, 2000